Cediranib
Information
- Drug Name
- Cediranib
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| ovarian cancer | BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION | B |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 3 | 25218906 | Detail |
| ovarian cancer | BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION | B |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 3 | 25218906 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| 46 women with platinum-sensitive, high-grade, BRCA... | BRCA1 | BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION | Sensitivity | true | CIViC Evidence | detail |
| 46 women with platinum-sensitive, high-grade, BRCA... | BRCA2 | BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01391962 | Active, not recruiting | Phase 2 | Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | July 18, 2011 | March 15, 2025 |
| NCT00750841 | Active, not recruiting | Phase 1 | Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours | September 9, 2008 | December 31, 2024 |
| NCT03334617 | Active, not recruiting | Phase 2 | Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy | December 18, 2017 | September 4, 2024 |
| NCT02502266 | Active, not recruiting | Phase 2/Phase 3 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | May 3, 2016 | June 30, 2024 |
| NCT03851614 | Active, not recruiting | Phase 2 | Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors | April 8, 2019 | January 1, 2025 |
| NCT01364051 | Active, not recruiting | Phase 1 | Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies | May 25, 2011 | March 7, 2025 |
| NCT02893917 | Active, not recruiting | Phase 2 | Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | August 11, 2017 | June 7, 2025 |
| NCT03660826 | Active, not recruiting | Phase 2 | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | September 27, 2018 | December 31, 2024 |
| NCT02974621 | Active, not recruiting | Phase 2 | Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | December 7, 2017 | July 20, 2024 |
| NCT03117933 | Completed | Phase 2 | Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | March 9, 2017 | December 31, 2023 |
| NCT02340611 | Completed | Phase 2 | A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib | June 2015 | June 2018 |
| NCT00384176 | Completed | Phase 2/Phase 3 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX | August 30, 2006 | August 19, 2015 |
| NCT02681237 | Completed | N/A | A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer | April 29, 2016 | March 25, 2022 |
| NCT02855697 | Completed | Early Phase 1 | Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer | May 26, 2017 | December 31, 2021 |
| NCT01208051 | Completed | Phase 1/Phase 2 | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | September 9, 2010 | February 1, 2020 |
| NCT00399035 | Completed | Phase 3 | Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer | November 2006 | August 2016 |
| NCT00423332 | Completed | Phase 2 | Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma | January 2007 | October 2016 |
| NCT00503204 | Completed | Phase 1 | Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour | September 2007 | December 2008 |
| NCT00306891 | Completed | Phase 2 | Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™) | June 2006 | September 2008 |
| NCT00777153 | Completed | Phase 3 | Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma | October 2008 | September 2016 |
| NCT00939848 | Completed | Phase 2/Phase 3 | Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers | April 2011 | September 2014 |
| NCT00960349 | Completed | Phase 1 | Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients | August 2009 | March 2011 |
| NCT01065662 | Completed | Phase 1 | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | February 2010 | March 2021 |
| NCT04090567 | Recruiting | Phase 2 | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | July 28, 2020 | March 31, 2025 |
| NCT02484404 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | June 29, 2015 | December 30, 2025 |
| NCT03741426 | Recruiting | Phase 2 | WIRE - Novel Treatments in Renal Cell Cancer | July 27, 2020 | November 30, 2025 |
| NCT02899728 | Terminated | Phase 2 | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer | March 30, 2018 | March 17, 2020 |
| NCT03278717 | Unknown status | Phase 3 | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients | June 15, 2018 | December 2023 |
| NCT03570437 | Unknown status | Phase 2 | Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? | May 17, 2018 | June 30, 2023 |
| NCT00532194 | Unknown status | Phase 3 | An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer | July 2007 | December 2016 |
| NCT01337401 | Unknown status | Phase 2 | A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS) | July 2011 | January 2020 |
| NCT03314740 | Unknown status | Phase 2 | Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib | June 1, 2017 | November 30, 2019 |